ALG-055009 vs Resmetirom

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

MASH / NASH

Shared mechanism: Thyroid hormone receptor-beta · full MASH / NASH pipeline

ALG-055009

Developed by Aligos Therapeutics

Phase 2 in MASH / NASHsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Resmetirom · Rezdiffra

Marketed by Madrigal Pharmaceuticals

Approved in MASH / NASHsmall molecule
Partial signal

NCT03900429 · Phase 3 · active, not recruiting

MAESTRO-NASH was a randomized, double-blind, placebo-controlled Phase 3; the month-12 analysis included 888 patients with F2-F3 fibrosis. Both doses met both liver-biopsy endpoints. Biopsy histology is a surrogate that supported accelerated approval, not a clinical outcome, so the grade is moderate.

Next expected readout: December 2026 · NCT05500222 (registry estimate)

Reported efficacy

Week 52 Dual Primary Objectives: To determine the effect of 80 or 100 mg MGL-3196 vs matching placebo on liver biopsy (NASH CRN score) at Week 52 compared with Baseline (52 weeks); Month 54 Primary Objective: Time to experiencing an adjudicated Composite Clinical Outcome event (Final Primary Endpoint, at 54 months) (up to 54 months): Month-12 histology (n=888): MASH resolution without fibrosis worsening 26-27% (80 mg) and 24-36% (100 mg) vs 9-13% placebo; fibrosis improvement without MASH worsening 23% (80 mg) and 24-28% (100 mg) vs 13-15% placebo (ranges across the two pathologists); both endpoints statistically significant for both doses (REZDIFFRA label, Trial 1). (met)

Result source: NCT03900429

Results for MASH / NASH

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointALG-055009Resmetirom
MASH resolution without fibrosis worsening—Not reported27.4% vs 14.7%+12.7 vs placebowk 36 · n 73NCT02912260
Fibrosis stage, change—Not reported—Not posted · NCT04197479
Liver fat (MRI-PDFF), change—Not reported-8.2% vs -2.9%−5.3 vs placebowk 36 · n 74NCT02912260
1 other result
  • -7% vs -2.7% wk 12 · n 78 · Phase 2 · secondary NCT02912260
ALT, change—Not reported-15.4 vs 11−26.4 vs placebowk 36 · n 78NCT02912260
1 other result
  • -8.2 vs -5.2 wk 12 · n 78 · Phase 2 · secondary NCT02912260

MASH resolution without fibrosis worsening

ALG-055009
—Not reported
Resmetirom
27.4% vs 14.7%+12.7 vs placebowk 36 · n 73NCT02912260

Fibrosis stage, change

ALG-055009
—Not reported
Resmetirom
—Not posted · NCT04197479

Liver fat (MRI-PDFF), change

ALG-055009
—Not reported
Resmetirom
-8.2% vs -2.9%−5.3 vs placebowk 36 · n 74NCT02912260
1 other result
  • -7% vs -2.7% wk 12 · n 78 · Phase 2 · secondary NCT02912260

ALT, change

ALG-055009
—Not reported
Resmetirom
-15.4 vs 11−26.4 vs placebowk 36 · n 78NCT02912260
1 other result
  • -8.2 vs -5.2 wk 12 · n 78 · Phase 2 · secondary NCT02912260
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ALG-055009: no structured comparison results are available for MASH / NASH.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ALG-055009: 0 of 4 rows · Resmetirom: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricResmetirom
Dropout rate
—Extension Studya
NCT02912260 · Phase 2 · registry result, not featured evidence
show 2 more results
11.9%MGL-3196
NCT02912260 · Phase 2 · registry result, not featured evidence
—MGL-3196 Main Study
NCT02912260 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—Extension Studya
NCT02912260 · Phase 2 · registry result, not featured evidence
show 2 more results
3.6%MGL-3196
NCT02912260 · Phase 2 · registry result, not featured evidence
—MGL-3196 Main Study
NCT02912260 · Phase 2 · registry result, not featured evidence
Serious AEs
0%Extension Studya
NCT02912260 · Phase 2 · registry result, not featured evidence
show 2 more results
—MGL-3196
NCT02912260 · Phase 2 · registry result, not featured evidence
6%MGL-3196 Main Study
NCT02912260 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
nasopharyngitis 9.7% (placebo 4.9%)
abdominal discomfort 6.5% (placebo 0%)
constipation 6.5% (placebo 0%)
NCT02912260 · Phase 2 · registry result, not featured evidence
show 1 more result
diarrhoea 36.9% (placebo 9.8%)
nausea 20.2% (placebo 4.9%)
headache 13.1% (placebo 14.6%)
NCT02912260 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Resmetirom

Hepatic Fat Fraction -32.9% (n=78) vs -10.4% (n=38) placebo @ 12wk
percent change · % of baseline
NCT02912260 · Phase 2 · registry result, not featured evidence
show 1 more result
-37.3% (n=74) vs -8.9% (n=34) placebo @ 36wk
NCT02912260 · Phase 2 · registry result, not featured evidence
Liver Fat -7% (n=78) vs -2.7% (n=38) placebo @ 12wk
absolute change · percentage points
NCT02912260 · Phase 2 · registry result, not featured evidence
show 1 more result
-8.2% (n=74) vs -2.9% (n=34) placebo @ 36wk
NCT02912260 · Phase 2 · registry result, not featured evidence
Hepatic Fat Fraction 30% Reduction 60.3% (n=78) vs 18.4% (n=38) placebo @ 12wk
responder rate · % of participants
NCT02912260 · Phase 2 · registry result, not featured evidence
show 1 more result
67.6% (n=74) vs 29.4% (n=34) placebo @ 36wk
NCT02912260 · Phase 2 · registry result, not featured evidence
NAS 1-Point Reduction 76.7% (n=73) vs 64.7% (n=34) placebo @ 36wk
responder rate · % of participants
NCT02912260 · Phase 2 · registry result, not featured evidence
NAS 2-Point Reduction 56.2% (n=73) vs 32.4% (n=34) placebo @ 36wk
responder rate · % of participants
NCT02912260 · Phase 2 · registry result, not featured evidence
NAS 2-Point Reduction With Inflammation Or Ballooning Improvement 50.7% (n=73) vs 32.4% (n=34) placebo @ 36wk
responder rate · % of participants
NCT02912260 · Phase 2 · registry result, not featured evidence
NAS Improvement 2 Points Without Fibrosis Progression 45.2% (n=73) vs 32.4% (n=34) placebo @ 36wk
responder rate · % of participants
NCT02912260 · Phase 2 · registry result, not featured evidence
Hepatocellular Steatosis Reduction 61.6% (n=73) vs 44.1% (n=34) placebo @ 36wk
responder rate · % of participants
NCT02912260 · Phase 2 · registry result, not featured evidence
Lobular Inflammation Reduction 21.9% (n=73) vs 17.6% (n=34) placebo @ 36wk
responder rate · % of participants
NCT02912260 · Phase 2 · registry result, not featured evidence
Hepatocellular Ballooning Reduction 58.9% (n=73) vs 58.8% (n=34) placebo @ 36wk
responder rate · % of participants
NCT02912260 · Phase 2 · registry result, not featured evidence
NASH Resolution Without Fibrosis Worsening 27.4% (n=73) vs 14.7% (n=34) placebo @ 36wk
responder rate · % of participants
NCT02912260 · Phase 2 · registry result, not featured evidence
CRP 29.3% (n=79) vs 13.2% (n=39) placebo @ 12wk
percent change · % of baseline
NCT02912260 · Phase 2 · registry result, not featured evidence
show 1 more result
90.9% (n=79) vs 34% (n=39) placebo @ 36wk
NCT02912260 · Phase 2 · registry result, not featured evidence

+ 3 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALG-055009's landscape · Resmetirom's landscape